For the quarter ended December 2023, Sarepta Therapeutics (SRPT - Free Report) reported revenue of $396.78 million, up 53.5% over the same period last year. EPS came in at $0.47, compared to -$1.24 in the year-ago quarter.
The reported revenue represents a surprise of +3.84% over the Zacks Consensus Estimate of $382.11 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1666.67%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $365.07 million versus the seven-analyst average estimate of $365.54 million.
- Revenues- Collaboration: $31.71 million versus the seven-analyst average estimate of $21.91 million.
- Revenues- Product, net- EXONDYS 51: $131.02 million versus the four-analyst average estimate of $139.26 million.
- Revenues- Product, net- AMONDYS 45: $69.92 million versus the four-analyst average estimate of $64.56 million.
- Revenues- Product, net- VYONDYS 53: $32.88 million versus $30.47 million estimated by four analysts on average.
- Revenues- Product, net- ELEVIDYS: $131.25 million versus the two-analyst average estimate of $131.15 million.
View all Key Company Metrics for Sarepta Therapeutics here>>>Shares of Sarepta Therapeutics have returned +18.8% over the past month versus the Zacks S&P 500 composite's +4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
For the quarter ended December 2023, Sarepta Therapeutics (SRPT - Free Report) reported revenue of $396.78 million, up 53.5% over the same period last year. EPS came in at $0.47, compared to -$1.24 in the year-ago quarter.
The reported revenue represents a surprise of +3.84% over the Zacks Consensus Estimate of $382.11 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1666.67%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $365.07 million versus the seven-analyst average estimate of $365.54 million.
- Revenues- Collaboration: $31.71 million versus the seven-analyst average estimate of $21.91 million.
- Revenues- Product, net- EXONDYS 51: $131.02 million versus the four-analyst average estimate of $139.26 million.
- Revenues- Product, net- AMONDYS 45: $69.92 million versus the four-analyst average estimate of $64.56 million.
- Revenues- Product, net- VYONDYS 53: $32.88 million versus $30.47 million estimated by four analysts on average.
- Revenues- Product, net- ELEVIDYS: $131.25 million versus the two-analyst average estimate of $131.15 million.
View all Key Company Metrics for Sarepta Therapeutics here>>>Shares of Sarepta Therapeutics have returned +18.8% over the past month versus the Zacks S&P 500 composite's +4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on SRPT - FREE